NCT06466655View on ClinicalTrials.gov

Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

April 10, 2025

Study Completion Date

May 29, 2025

Conditions
Middle-aged AdultsMajor Depressive Disorder
Interventions
DRUG

MitoTempol

One intradermal microdialysis probes will be perfused with MitoTempol (0.5 mM) during a standard local skin heating protocol.

DRUG

Lactated Ringer's (control)

One intradermal microdialysis probes will be perfused with lactated Ringer's (control) during a standard local skin heating protocol.

Trial Locations (1)

19713

University of Delaware, Newark

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

University of Delaware

OTHER

NCT06466655 - Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline | Biotech Hunter | Biotech Hunter